MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploi...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Elsevier 2023-10-01
Seri Bilgileri:Cell Reports
Konular:
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2211124723012330

Benzer Materyaller